Claims
- 1. A method of detecting a target nucleic acid in a sample, the method comprising:
providing at least a first and second group of nucleic acid probes, the first group of probes comprising at least 10% of all possible nucleic acid probes having x number of nucleotides and the second group of probes including at least 10% of all possible nucleic acid sequences having at least y number of nucleotides; hybridizing at least a first probe from the first group and at least a second probe from the second group to target nucleic acid; and, detecting the hybridization by a non-Sanger detection step, thereby detecting the target nucleic acid.
- 2. The method of claim 1, wherein the first and second probes are substantially proximal when hybridized to the target nucleic acid, wherein proximity of the first probe to the second probe stabilizes binding of at least one of the first and second probes.
- 3. The method of claim 1, further comprising ligating the first and second probes.
- 4. The method of claim 1, wherein x or y is an integer between about 5 to about 10, inclusive.
- 5. The method of claim 1, wherein x or y is an integer between about 6 to about 9, inclusive.
- 6. The method of claim 1, wherein x or y is 7.
- 7. The method of claim 1, wherein x=y.
- 8. The method of claim 1, wherein x or y is an integer between about 5 and about 18, inclusive.
- 9. The method of claim 1, wherein x or y is an integer between about 7 and about 12, inclusive.
- 10. The method of claim 1, wherein x or y is 10.
- 11. The method of claim 1, wherein the first and second groups are components of a single physical group.
- 12. The method of claim 1, wherein the first and second groups are components of a plurality of physical groups.
- 13. The method of claim 1, wherein the first or second probes comprise at least one promiscuous base.
- 14. The method of claim 13, wherein the at least one promiscuous base is selected from a group consisting of: inosine, and azidothimidine.
- 15. The method of claim 1, wherein the first or second groups comprise one or more of: a nucleobase analog, a sugar analog, or an internucleotide analog.
- 16. The method of claim 1 or 15, wherein the first or second groups comprise at least 60% of all possible nucleic acid probe sequences having x or y nucleotides.
- 17. The method of claim 1 or 15, wherein the first or second groups comprise at least 70% of all possible nucleic acid probe sequences having x or y nucleotides.
- 18. The method of claim 1 or 15, wherein the first or second groups comprise at least 80% of all possible nucleic acid probe sequences having x or y nucleotides.
- 19. The method of claim 1 or 15, wherein the first or second groups comprise at least 90% of all possible nucleic acid probe sequences having x or y nucleotides.
- 20. The method of claim 1 or 15, wherein the first or second groups comprise at least 95% of all possible nucleic acid probe sequences having x or y nucleotides.
- 21. The method of claim 1, wherein the first or second group further comprise probes of length w, wherein w is not equal to x or y.
- 22. The method of claim 1, wherein the first or second group further comprise probes of length w, wherein w is not equal to x or y, wherein a Tm of the probes of the first or second group, or both the first and second group, are selected to be approximately equal.
- 23. The method of claim 15, wherein the nucleobase analogs include covalently bound minor groove binders or intercalators that enhance hybridization avidity or specificity of the first or second probes to the target nucleic acid.
- 24. The method of claim 15, wherein the internucleotide analogs comprise one or more of: a phosphate ester analog, or a non-phosphate oligonucleotide analog.
- 25. The method of claim 24, wherein the non-phosphate oligonucleotide analog is a PNA.
- 26. The method of claim 24, wherein the phosphate ester analogs are selected from a group consisting of conformationally restricted nucleotides, alkyl phosphonates, phosphoroamidates, alkylphosphotriesters, phosphorothioates, and phosphorodithioates.
- 27. The method of claim 1, wherein the first probe is labeled with a fluorescent reporter moiety, and the second probe is labeled with a quencher moiety, such that upon hybridization of the probes with the target nucleic acid, fluorescence of the reporter moiety is quenched, thereby reducing fluorescence of the reporter moiety.
- 28. The method of claim 27, wherein the reporter and quencher moieties are selected from pairs of reporters and quenchers comprising: terbium chelate and TRITC (tetrarhodamine isothiocyanate), europium cryptate and Allophycocyanin, DABCYL and EDANS, Fluorescein and Tetramethylrhodamine, IAEDANS and Fluorescein, Fluorescein and Fluorescein, BODIPY FL and BODIPY FL, and Fluorescein and QSY 7 dye.
- 29. The method of claim 1, wherein the first probe is labeled with a fluorescent reporter moiety at one of its termini, and the second probe is labeled with a quencher moiety at one of its termini, such that hybridization of the first and second probes with the target nucleic acid causes an increase in fluorescence emission.
- 30. The method of claim 29, or 29, wherein detecting hybridization of the first or second probes comprises fluorescence resonance energy transfer (FRET) detection.
- 31. The method of claim 29, or 29, wherein the fluorescent reporter moiety is selected from a group consisting of: Xanthene dyes, Cyanine dyes, and Metal-Ligand Complexes.
- 32. The method of claim 29, or 29, wherein the first and second probes comprise a FRET pair.
- 33. The method of claim 1, further comprising at least a third group of nucleic acid probes comprising at least 10% of all nucleic acid probe sequences having z nucleotides, wherein the method further comprises hybridizing at least a third probe from the third group to the target nucleic acid substantially proximal to at least one of the first and second probes.
- 34. The method of claim 33, further comprising ligating the first, second and third probes together with a ligase.
- 35. The method of claim 33, wherein the first and second probes are hybridized to the target nucleic acid in a mixture comprising a buffer.
- 36. The method of claim 33, wherein the probes from the second and third groups are each labeled with a label.
- 37. The method of claim 36, wherein the label of the probes from the second group is different from the label of the probes from the third group.
- 38. The method of claim 37, wherein the at least one probe from the second group is labeled with a fluorescent reporter dye at one of its termini, and the at least one probe from the third group is labeled with a quencher molecule at one of its termini, such that upon hybridization of the probes from the first, second and third groups with the sample, the fluorescence of the reporter dye is quenched so as to cause a reduction in fluorescence emission of the reporter dye.
- 39. The method of claim 1, wherein the detecting step comprises observing the fluorescence of the hybridized probes while varying temperature over a range of temperatures.
- 40. The method of claim 39, wherein the range of temperatures during which fluorescence is observed is from about 0° C. to about 60° C.
- 41. The method of claim 1, wherein the target nucleic acid comprises a polymorphic variant sequence.
- 42. The method of claim 41, wherein the first probe is fully complementary to the polymorphic variant sequence and the second probe hybridizes substantially adjacent to the polymorphic variant sequence.
- 43. The method of claim 41, wherein detecting the target nucleic acid comprises detecting the polymorphic variant sequence.
- 44. The method of claim 41, wherein the target nucleic acid is derived from a patient, an animal, a plant, a bacteria, a fungi, an archae, a cell, a tissue, or an organism.
- 45. The method of claim 41, wherein the target nucleic acid is derived from a bacteria, archae, plant, non-human animal, cell, fungi, or non-human organism and the method further comprises selecting the a bacteria, archae, plant, non-human animal, cell, fungi, or non-human organism based upon detection of the target nucleic acid.
- 46. The method of claim 41, wherein the target nucleic acid is derived from a patient.
- 47. The method of claim 46, wherein the method further comprises selecting a treatment, diagnosing a disease, or diagnosing a genetic predisposition to a disease, based upon detection of the target nucleic acid.
- 48. The method of claim 1, wherein the first and second probes are hybridized to the target nucleic acid in a mixture comprising a buffer.
- 49. A method for detecting a polymorphic variant in a polymorphic nucleic acid sequence, the method comprising:
flowing a mixture comprising a polymorphic nucleic acid sequence, at least two probes and a buffer into an analysis channel, one of the at least two probes being complementary to a portion of the polymorphic nucleic acid sequence comprising the polymorphic variant, and the other probe being complementary to a substantially adjacent portion of the polymorphic nucleic acid sequence; and, detecting hybridization of at least one of the at least two probes to determine the identity of the polymorphic variant in the polymorphic nucleic acid sequence by varying temperature within a detection region located at a position along a length of the analysis channel.
- 50. The method of claim 48 or 49, wherein the mixture comprises a salt in a concentration from a range of about 0.2M to about 2M.
- 51. The method of claim 48 or 49, wherein the salt concentration is in the range of about 0.5M to about 1.5M.
- 52. The method of claim 48 or 49, wherein the salt concentration is in the range of about 0.8M to about 1.2 M.
- 53. The method of claim 48 or 49, wherein the salt concentration is about 1M.
- 54. The method of claim 49, wherein the detecting step comprises measuring a signal intensity resulting from hybridization of the hybridizing probes and the target nucleic acid.
- 55. The method of claim 49, wherein the method comprises providing the analysis channel in a microfluidic device, wherein the analysis channel comprises one or more detection regions and one or more temperature control regions.
- 56. A method of detecting a target nucleic acid, the method comprising:
flowing a mixture comprising the target nucleic acid in an analysis channel; flowing at least a first probe and a second probe into the analysis channel; hybridizing a first probe to the target nucleic acid; hybridizing a second probe to the target nucleic acid, wherein the second probe hybridizes to the target nucleic acid substantially adjacent to the first probe, and wherein hybridization of the second probe stabilizes hybridization of the first probe; and, detecting hybridization of the first probe by a non-Sanger detection step.
- 57. The method of claim 56, wherein the target nucleic acid is derived from a patient, an animal, a plant, a bacteria, a fungi, an archae, a cell, a tissue, or an organism.
- 58. The method of claim 56, wherein the target nucleic acid comprises a polymorphic sequence.
- 59. The method of claim 56, wherein the first or second probe comprises a fluorescent label.
- 60. The method of claim 59, wherein the first probe comprises a first label and the second probe comprises a second label, wherein the first label is quenched by proximity to the second label.
- 61. The method of claim 60, wherein the first probe and the second probe collectively comprise a FRET label pair.
- 62. The method of claim 56, wherein the first or second probe is provided from at least one probe set comprising at least 10% of all possible nucleic acids of a selected type for a selected length, wherein the selected length is at least about 5 probe monomers.
- 63. The method of claim 56, wherein the first probe and the second probe are independently selected from at least two groups of probes, each comprising at least 10% of all possible nucleic acids of a selected type for a selected length, wherein the selected length for each of the two groups is at least about 5 probe monomers.
- 64. The method of claim 56, wherein the first probe and the second probe are independently selected from at least two groups of probes, each comprising at least 10% of all possible nucleic acids of a selected type for a selected length, wherein the selected length for each of the two groups is at least about 5 probe monomers, the method further comprising hybridizing a third probe to the target nucleic acid, wherein the third probe is selected from a third group of probes comprising at least 10% of all possible nucleic acids of a selected type for a selected length, wherein the selected length is at least about 5 probe monomers.
- 65. The method of claim 64, wherein the first, second or third group of probes comprises at least two probe sizes.
- 66. The method of claim 65, wherein the at least two probe sizes are selected to have an approximately equal Tm.
- 67. The method of claim 62, wherein the probe monomers comprise one or more of: a nucleotide, or a PNA monomer.
- 68. The method of claim 56, wherein the first probe is provided from at least one probe set comprising at least 10% of all possible nucleic acids of a selected type for a selected length, wherein the selected length is at least 5 probe monomers and the second probe is provided from at least a second probe set comprising at least 10% of all possible nucleic acids of a selected type for a selected length, wherein the selected length is at least about 5 probe monomers.
- 69. The method of claim 56, wherein detection of hybridization of the first probe comprises detecting FRET between a first label on the first probe and a second label on the second probe.
- 70. The method of claim 56, wherein the first and second probes are components of a single physical group.
- 71. The method of claim 56, wherein the first and second probes are components of multiple physical groups.
- 72. The method of claim 56, wherein the mixture comprises a salt in a concentration from a range of about 0.2M to about 2M.
- 73. The method of claim 56, wherein the salt concentration is in the range of about 0.5M to about 1.5M.
- 74. The method of claim 56, wherein the salt concentration is in the range of about 0.8M to about 1.2 M.
- 75. The method of claim 56, wherein the salt concentration is about 1M.
- 76. A set of nucleic acid probes for detection of a target nucleic acid sequence in a sample, comprising:
at least two groups of nucleic acid probes, a first of the at least two groups comprising at least 10% of all possible nucleic acid probe sequences having x nucleotides, and a second of the at least two groups comprising at least 10% of all possible nucleic acids having y nucleotides; wherein a plurality of members of each of the first and second groups are labeled.
- 77. The set of claim 76, wherein labels of the members of the first group interact with labels of the second group, when the labels are in proximity to one another.
- 78. The set of claim 76, wherein hybridization of a member of the first group to the target nucleic acid stabilizes hybridization of a member of the second group.
- 79. The set of claim 76, wherein the two groups include at least 60% of all possible nucleic acid probe sequences for nucleic acid probes of length x or y.
- 80. The set of claim 76, wherein the two groups include at least 70% of all possible nucleic acid probe sequences for nucleic acid probes of length x or y.
- 81. The set of claim 76, wherein the two groups include at least 80% of all possible nucleic acid probe sequences for nucleic acid probes of length x or y.
- 82. The set of claim 76, wherein the two groups include at least 90% of all possible nucleic acid probe sequences for nucleic acid probes of length x or y.
- 83. The set of claim 76, wherein the two groups include at least 95% of all possible nucleic acid probe sequences for nucleic acid probes of length x or y.
- 84. The set of claim 76, wherein the probes of the first group comprise a first label and the probes of the second group comprise a second label.
- 85. The set of claim 84, wherein the first label comprises an acceptor FRET moiety and the second label comprises a donor FRET moiety.
- 86. The set of claim 85, wherein the acceptor moiety comprises a quencher moiety.
- 87. The set of claim 86, wherein the quencher is selected from a group consisting of: fluorophores, Dabsyl, Black-hole™, QSY™, and an Eclipse Dark Quencher.
- 88. The set of claim 85, wherein the donor is selected from a group consisting of: Xanthene dyes, Cyanine dyes, Metal-Ligand Complexes, Coumarin dyes, BODIPY dyes, and Pyrene dyes.
- 89. The set of claim 76, wherein at least one of the at least two groups further comprise a subset of probes having w number of nucleotides, wherein when present in the first set, w is not equal to x and when present in the second set w is not equal to y.
- 90. The set of nucleic acid probes of claim 76, wherein the first or second groups comprise probes of a length other than x or y, respectively.
- 91. The set of nucleic acid probes of claim 89, wherein w is an integer between about 1 and about 10, inclusive.
- 92. The set of nucleic acid probes of claim 89, wherein w is an integer between about 1 and about 8, inclusive.
- 93. The set of claim 76, further comprising at least a third group of nucleic acid probes comprising at least 10% of all nucleic acid probe sequences having z nucleotides.
- 94. The set of nucleic acid probes of claim 93, wherein z is an integer between about 5 and about 10, inclusive.
- 95. The set of nucleic acid probes of claim 76, wherein x is an integer between about 5 and about 10, inclusive.
- 96. The set of nucleic acid probes of claim 76, wherein x is an integer between about 6 and about 9, inclusive.
- 97. The set of nucleic acid probes of claim 76, wherein x is 7.
- 98. The set of nucleic acid probes of claim 76, wherein x=y.
- 99. The set of nucleic acid probes of claim 76, wherein y is an integer between about 5 and about 18, inclusive.
- 100. The set of nucleic acid probes of claim 76, wherein y is an integer between about 7 and about 12, inclusive.
- 101. The set of nucleic acid probes of claim 76, wherein y is 10.
- 102. The set of nucleic acid probes of claim 76, wherein the first and second groups are components of a single physical group.
- 103. The set of nucleic acid probes of claim 76, wherein the first and second groups are components of a plurality of physical groups.
- 104. A library of nucleic acids, comprising:
at least about 10% of all possible nucleic acids for a monomer length x, wherein x is greater than or equal to 5, wherein the nucleic acids comprise non-natural nucleic acid monomers.
- 105. The library of claim 104, wherein the nucleic acids of the library display greater avidity or specificity for a target nucleic acid than a corresponding natural nucleic acid.
- 106. The library of claim 104, wherein the nucleic acids of the library comprise one or more of: a PNA, an LNA, and a base-modified nucleic acid.
- 107. The library of claim 104, wherein the nucleic acids of the library comprise one or more of: a nucleobase analog, a sugar analog, or an internucleotide analog.
- 108. The library of claim 104, wherein the nucleic acids of the library comprise one or more labels.
- 109. The library of claim 108, wherein the labels of the library comprise one or more fluorescent, luminescent, or colorimetric labels.
- 110. The library of claim 108, wherein the labels of the library comprise one or more FRET pairs.
- 111. The library of claim 104, wherein at least 90% of the 10% comprise of one or more of: a PNA, an LNA, and a base-modified nucleic acid.
- 112. The library of claim 104, wherein at least 90% of the 10% consist of one or more of: a PNA, an LNA, and a base-modified nucleic acid.
- 113. The library of claim 104, comprising at least about 10% of all possible nucleic acids for a monomer length y, wherein y is greater than or equal to 5 and does not equal x, and wherein the nucleic acids comprise non-natural nucleic acid monomers.
- 114. The library of claim 113, comprising at least about 10% of all possible nucleic acids for a monomer length z, wherein z is greater than or equal to 5 and does not equal x or y, and wherein the nucleic acids comprise non-natural nucleic acid monomers.
- 115. The library of claim 104, wherein the members of the library are arranged in substantially separate pools.
- 116. The library of claim 104, wherein the members of the library are arranged in substantially overlapping pools.
- 117. The library of claim 104, wherein the members of the library are arranged dried on a solid surface in a re-hydrateable form.
- 118. The library of claim 104, wherein the members of the library are arranged in microtiter wells.
- 119. The library of claim 104, wherein the members of the library are arranged in a microfluidic system.
- 120. The library of claim 104, wherein the members of the library are arranged in a format accessible by a microfluidic system.
- 121. A genetic analysis system, comprising:
a vessel comprising a mixture, the mixture comprising a target nucleic acid; a plurality of sources of nucleic acid probes, the plurality of sources each including probes of at least 10% of all possible nucleic acid probe sequences of length x or y; and, a system for selectively delivering different probes from the plurality of sources of probes to the vessel, comprising: system instructions which identify and select probes to be delivered to the vessel; and a sampling system for sampling and delivering probes from the plurality of sources of probes to the vessel, wherein the vessel is a microfluidic device, and the system instructions select probes that are complementary to a region of interest on the target nucleic acid.
- 122. The system of claim 121, wherein the sampling system comprises a pipettor affixed to the microfluidic device.
- 123. The system of claim 121, wherein the sampling and delivering probes comprises delivering at least three nucleic acid probes from the plurality of sources of probes to the vessel.
- 124. The system of claim 121, wherein the nucleic acid probes comprise hybridizing probes and flanking sequences, the hybridizing probes comprising at least one interrogation base.
- 125. The system of claim 124, wherein at least one of the hybridizing probes comprises one or more of: nucleobase analogs, sugar analogs, or internucleotide analogs in its sequence.
- 126. The system of claim 125, wherein the nucleobase analogs include covalently bound minor groove binders, intercalators or other modifications for enhancing hybridization avidity or specificity of the nucleic acid probes.
- 127. The system of claim 125, wherein the nucleobase analogs include non-covalently bound minor groove binders selected from a group consisting of DAPI, and Hoeschst 33258.
- 128. The system of claim 125, wherein the internucelotide analogs comprise one or more of: a phosphate ester analog, or a non-phosphate oligonucleotide analog.
- 129. The system of claim 125, wherein the phosphate ester analogs are selected from a group consisting of alkyl phosphonates, phosphoroamidates, alkylphosphotriesters, phosphorothioates, and phosphorodithioates.
- 130. The system of claim 121, wherein the plurality of sources of nucleic acid probes comprise sources of at least 75% of all possible nucleic acid probe sequences of length x or y
- 131. The system of claim 121, wherein the plurality of sources of nucleic acid probes comprise sources of at least 85% of all possible nucleic acid probe sequences of length x or y.
- 132. The system of claim 121, wherein the plurality of sources of nucleic acid probes comprise sources of at least 95% of all possible nucleic acid probe sequences of length x or y.
- 133. The system of claim 121, wherein the vessel is in contact with a thermal element, whereby at least a region of the vessel is subjected to an increase or decrease in temperature.
- 134. The system of claim 121, wherein x or y is an integer between about 5 and about 10, inclusive.
- 135. The system of claim 121, wherein x or y is an integer between about 6 and about 9, inclusive.
- 136. The system of claim 121, wherein at least one of x or y is 7.
- 137. The system of claim 121, wherein at least one of x or y is 6.
- 138. The system of claim 121, further comprising a detector.
- 139. The system of claim 121, wherein the microfluidic device comprises at least two intersecting microscale channels wherein at least one of the at least two intersecting channels is an analysis channel.
- 140. The system of claim 139, wherein the analysis channel is subjected to an increase or decrease in temperature.
- 141. The system of claim 121, wherein the mixture comprises salt in a concentration from about 0.2M to about 2M.
- 142. The system of claim 141, wherein the salt concentration is in a range of from about 0.5M to 1.5M.
- 143. The system of claim 141, wherein the salt concentration is in a range of from about 0.8M to 1.2 M.
- 144. The system of claim 141, wherein the salt concentration is 1M.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to and benefit of U.S. Provisional Patent Application No. 60/283,527, filed on Apr. 12, 2001. The full disclosure of this prior application is incorporated by reference herein.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0002] The present invention was made with government funding from the United States National Institute of Standards and Technology (NIST), through the Advanced Technology Program (ATP) under Grant No. 70NANB8H4000, and the United States government has certain rights in the invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60283527 |
Apr 2001 |
US |